Takeda to Acquire TiGenix for €520M

Takeda Pharmaceutical said today it has agreed to acquire stem cell therapy developer TiGenix for up to €520 million ($632 million) in a deal designed to strengthen the buyer’s late-stage gastroenterology pipeline and presence in the U.S. specialty care market.The deal builds upon a partnership by the companies, through which TiGenix sold to Takeda ex-U.S. licensing rights to develop and commercialize Cx601 (darvadstrocel), an up-to-€390 million deal signed in July 2016 .Cx601 is